Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. R...
Age: 12 years - 66+
Gender: All
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
Transcranial Magnetic Stimulation in Misophonia
The purpose of the project is to assess the efficacy of parietal transcranial magnetic
stimulation in misophonia. N=60 participants will undergo two transcranial magnetic
stimulation sessions: one inhibitory and another excitatory. During both sessions, the
parietal ...
Age: 18 - 55 years
Gender: All
MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The most common symptoms are...
Age: 18 years - 66+
Gender: All
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps
people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to
closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1
ulcer t...
Age: 18 years - 66+
Gender: All
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps
people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to
closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1
ulcer t...
Age: 18 years - 66+
Gender: All
Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)
Recent retrospective studies have demonstrated differences between pulse oximeter values
(SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or
Hispanic. These retrospective studies have limitations because self-reported race is
lik...
Age: Birth - 18 years
Gender: All
Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)
Recent retrospective studies have demonstrated differences between pulse oximeter values (SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or Hispanic. These retrospective studies have limitations because self-reported race is likely...
Age: Birth - 18 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease
which includes the forming of lumps, abscesses and scars in areas of the skin such as
under the breasts, under armpits, inner thighs, groin and buttocks. This study will
compare lu...
Age: 16 years - 66+
Gender: All
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
The purpose of this study is to learn about the safety and effects of 2 study medicines
(PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long-
lasting itchy red rash, caused by a skin reaction.
This study is seeking participants wh...
Age: 18 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing schedules of cemiplimab given in combination with cisplatin and docetaxel induction chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head and ...
Age: 18 years - 66+
Gender: All
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin
Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the
usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with
HER2 p...
Age: 18 years - 66+
Gender: Female
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin
Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the
usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with
HER2 p...
Age: 18 years - 66+
Gender: Female
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
The overall hypothesis is that treatment with the SGLT2 inhibitor Ertugliflozin induces a differential regulation in interstitial fluid vs plasma volume, with more reduction of the volume from the interstitial fluid than from the circulating plasma volume, which results...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab
(EPKINLY™), either by itself or together with other therapies, when treating subjects
with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to
identify t...
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpig...
Age: 18 years - 66+
Gender: All
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3
chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen
Receptor T cells [CABA-201]) in subjects with active, pemphigus vulgaris
Age: 18 years - 66+
Gender: All
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel
that can be applied to the skin (called transdermal delivery).
The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms.
Participants from the ZYN2...
Age: 3 - 29 years
Gender: All